TAE Life Sciences
  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Advisors
    • News
    • Events
    • Careers
  • BNCT
    • History
    • How it Works
    • Benefits of BNCT
    • BNCT Virtual Clinic
  • Pipeline
  • Technology
  • Contact Us
  • TAE.com
  • NEW EBOOK
  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Advisors
    • News
    • Events
    • Careers
  • BNCT
    • History
    • How it Works
    • Benefits of BNCT
    • BNCT Virtual Clinic
  • Pipeline
  • Technology
  • Contact Us
  • TAE.com
  • NEW EBOOK

News

Developing-targeted-drugs-for-boron-neutron-capture-therapy-to-treat-refractory-cancers
August 21, 2021

Developing targeted drugs for boron neutron capture therapy to treat refractory cancers

2021 | Nature Biopharmadealmakers | Read Now

TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.

VIDEO-Explaining-Boron-Neutron-Capture-Therapy-for-Targeted-Cancer-Radiotherapy
November 15, 2020

VIDEO: Explaining Boron Neutron Capture Therapy for Targeted Cancer Radiotherapy

2022 | ITOnline | Read Now

Bruce Bauer, Ph.D., CEO of TAE Life Sciences. The company is developing boron neutron capture therapy (BNCT) as a new radiation therapy for cancer. A patient is first infused with a non-toxic boron-10 compound, which selectively accumulates in tumor tissue. A neutron beam is then focused on the tumor and the neutrons are captured by the boron and causes emission of alpha radiation particles within the tumor.

TLS-and-RaySearch
July 15, 2020

RaySearch and TAE Life Sciences Announce Agreement on RayStation Support for the Alphabeam System for BNCT

2020 | Cision PR Newswire | Read Now

BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10.

OCBJ-logo
June 24, 2020

$30M for Cancer-Focused TAE Life Sciences

2020 | Orange County Business Journal | Read Now

HEALTHCARE: SPIN-OFF FROM FUSION COMPANY AIMING BIG

applied-radiology-logo
June 24, 2020

Tiny Yet Mighty: Nanotechnology in Radiation Therapy

2020 | Applied Radiation Oncology | Read Now

Nanotechnology is the application of extremely small things—a nanometer is one billionth of a meter—used in science, engineering and technology. It involves the ability to view and control individual atoms and molecules and has been used in designing new therapeutics and diagnostics in medicine. As such, interest is mounting to harness nanotechnology’s potential to enhance radiation therapy and advance cancer care.

BioWorld MedTech
March 15, 2018

New TAE Unit Launched To Treat Cancers Gains $40M In Financing And Closes Partnership Deal

2018 | BioWorld MedTech | Read Now

BNCT may provide a new option for patients with GBM and head and neck cancers due to its ability to leave healthy tissue unharmed.

Venture Funding News
March 13, 2018

TAE Life Sciences Inks $40M Series A Funding

2018 | VC News Daily | Read Now

TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.

massdevice
March 13, 2018

TAE Life Sciences Raises $40M For Neutron Beam Cancer Treatment

2018 | MassDevice| Read Now

TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.

Pharmaphorum
March 13, 2018

TAE Raises $40M To Develop New Targeted Radiotherapy

2018 | Pharmaphorum| Read Now

Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.

Newer
12
Older

Sign up for our latest news and information

* indicates required




TAE Life Sciences, 35 Parker, Irvine, CA 92618

* The TAE Life Sciences device and drugs are in development and not available for sale or commercial use

Copyright ©2023 TAE Life Sciences. All Rights Reserved. Privacy Policy